Page 2 - Dose Reduction News Today

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.

Expert oncologist Kevin Kalinsky, MD, MS, reviews a patient case of HER2+ metastatic breast cancer and highlights key findings in this disease setting.

The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.

The panel discusses the best approaches to treating patients with non-clear cell RCC.

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Mehmet Asim Bilen, MD, explains how he would treat a patient with renal cell carcinoma who had disease progression after adjuvant therapy.

The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.